Cardiovascular disease in women with breast cancer – a nationwide cohort study

BMC Cancer

Table 3 Hazard ratio (HR) of CVD in BC patients after different types of cancer treatment

	Model 1: CVD diagnosis in NPR [95% CI]	Model 2: CVD drug prescriptions in NPDR [95% CI]
Chemotherapy	1.180^*	1.365^***
Chemotherapy	[1.030;1.353]	[1.226;1.520]
Radiation therapy	0.996	1.131^*
Radiation therapy	[0.887;1.117]	[1.023;1.251]
Antibody therapy	1.029	1.032
Antibody therapy	[0.759;1.394]	[0.827;1.290]
Hormonal therapy	0.834	0.983
Hormonal therapy	[0.686;1.014]	[0.832;1.162]
No surgery	1.112	1.091
No surgery	[0.951;1.300]	[0.914;1.301]
Distant metastasis when diagnosed with BC	0.978	1.329^*
Distant metastasis when diagnosed with BC	[0.760;1.257]	[1.065;1.659]
Number of observations, N	13.783	8.819

95% confidence intervals in brackets. The following covariates were included in the models: Age, region of residence, education, cohort (year of diagnosis) and comorbidity at index date (CCI, diabetes or CVD (CVD at index date was defined by either CVD drug prescriptions in NPDR (model 1) or CVD diagnoses in NPR (model 2)). Comorbidity at index date was associated with an increased risk of CVD during the follow-up period no matter whether comorbidity was measured by CCI, diabetes or CVD
^* p < 0.05, ^** p < 0.01, ^*** p < 0.001

ISSN: 1471-2407